business
Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Key takeaways
- For a retirement-focused investor, one may be more temping now but the other may be the stronger long-term franchise.
- The analyst who called NVIDIA in 2010 just named his top 10 stocks and Eli Lilly wasn t one of them.
- Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma.
Pfizer vs Eli Lilly: Different Bets on Pharma M&A Trey Thoelcke Mon, May 11, 2026 at 8:05 PM GMT+7 3 min read LLY PFE NVDA Quick Read Eli Lilly (LLY) has shown revenue growth from a position of strength while Pfizer (PFE) is still rebuilding from the COVID cliff.
For a retirement-focused investor, one may be more temping now but the other may be the stronger long-term franchise.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Eli Lilly wasn t one of them. Get them here FREE.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop